PEROXISOME PUBLISHER ACTIVATED RECEPTORY AND 15 - PROSTAGLANDIN DEHYDROGENASE

The presence of PGE2 in lung carcinogenesis fuel the tumor microenvironment, The establishment of the strategic goal of both PGE2 chemopreventative and chemotherapy
As mentioned above, for the management of lung cancer. PGE2 to increase metabolism
Represents an alternative treatment to interfere with the clearance COX - 2 activity. Newly identified tumor suppressor and catabolic enzymes, PGE2 is converted to biologically inactive - 15 prostaglandin dehydrogenase (PGDH 15) 15 - keto derivatives and the like. Thus, 15 of the tumor - increase productivity PGDH Micros has the ability to inhibit tumor growth by reducing the concentration of Of PGE2 available to the tumor. Hazra and colleagues, reported in the recent Thiazolidinedione (TZD was), rosiglitazone and pioglitazone, a decrease in PGE2 Production lines at cell lung cancer, and 15 full - Sirna targeting PGDH Prevented the TZDs (146) effect. TZD class of antidiabetic and insulinsensitizing. Troglitazone, ciglitazone, rosiglitazone, pioglitazone and drugs including.
Biology, and TZD agonists of peroxisome publisher activated Receptor γ (PPARg), ligand activated nuclear receptors. One role PPARg has also recently been established and the organization of the metabolism of inflammatory Years, has been defining the role of TZDs in PPARg and cancer Were reviewed and a wide range (147-149) and the subject. Cox TZD - changes expression 2 Catabolic enzyme of PGE2 PGE2 production and as a result, 15 - prostaglandin Dehydrogenase by PPARg both dependent and independent (15 - PGDH)
Cox NSCLC - results in decreased expression of the two mechanisms, and inhibition
In vitro cell proliferation, inhibition of the growth of cancerous tumors in xenograft model, and. PPARg in the lungs, TZDs, and the interaction pathways COX-2/PGE2 Cancer are complex, to understand the mechanisms underlying this relationship May be useful in the design of anti-cancer therapy.
Li et al studied the effect of the PPARg agonist rosiglitazone In the laboratory (150) lung non-small cell cancer cell growth. Specifically, the expression is evaluated by And antitumor activity of EGFR TKI PTEN, gefitinib. Rosiglitazone treatment Limit the growth of A549 cells in a dose-dependent manner, to facilitate Antiproliferative effect of gefitinib. The PPARg expression of PTEN Increased in cells treated with rosiglitazone and gefitinib. According to these data, Increase the PPARg agonist rosiglitazone, and the antiproliferative effect of gefitinib in Suggests that the ligand functions as a treatment for PPARg, and increased expression of PTEN The goal of NSCLC. Mr. Reddy and her colleagues, the possibility of the use of ligands for PPARg, troglitazone survey In combination with cisplatin or paclitaxel, set NSCLC (151) inches Troglitazone showed a synergy between the interaction of these studies in the laboratory Mediated inhibition of cell proliferation in NSCLC with cisplatin and paclitaxel in Inhibition of a specific sequence occurs only when the growth in the troglitazone treatment Then, instead of chemotherapy, and vice versa. Cisplatin and paclitaxel are both upregulated Protein expression of PPARg, likely account for the specific sequence The nature of the benefit of combination therapy. Were obtained similar results Mouse xenograft model of NSCLC. This data, and demonstrate a novel sequence specific Synergy with chemotherapy agents for the treatment and PPARg ligands Non-small cell lung cancer. Girnun it will determine the effectiveness of the combination of rosiglitazone, Drug-resistant NSCLC (152) carboplatin treatment in preclinical models. Mouse With K - header or EGFR mutations in tumors given either rosiglitazone or carboplatin Single or a combination of both drugs. According to tumor burden and pathology,
The assessment of cell proliferation and apoptosis. Not change the burden of the tumor Increase in mice after treatment or by itself. In contrast, the suppression of large tumor
Occurs in response to combination therapy. It is clear that the analysis of the immune
Treatment decreased tumor cell proliferation and increased cell-mediated before. More importantly, no synergy between rosiglitazone and carboplatin is not Increase the systemic toxicity. These results, we suggest that the platinum drugs, Rosiglitazone, interact synergistically to reduce the burden of non-small cell lung cancer tumors in preclinical.
They also suggest that a combination of carboplatin PPARg ligand and its value Clinically, further investigation in these cancers, especially in the main screen Resistance to treatment and targeted treatment of acquired resistance to platinum. Kim and others, studied the expression and function of truncated paste Human PPARg in primary human lung cancer samples (153) variables. In PPARg expression was confined primarily to the nucleus of non-tumor tissue, Found in the nucleus and cytoplasm of the tumor from the SCC. In vitro studies using Chinese Hamster ovary cells showed overexpression of the alternative paste PPARg
Prepare for the cell death caused by chemotherapy or inhibition of oxidative stress Agent cisplatin, in turn, down regulation paste of variables, which makes Tumor cell sensitivity to cisplatin. Paste this option overexpression of PPARg, and cancer cells, and one mechanism to become resistant to these drugs and Chemical-induced cell death indicates that it has been linked to variable Paste, Tumor progression and diagnosis of the poor. In a recent retrospective study, GOVINDARAJAN and colleagues is important note Decreased risk of lung cancer in the population in the Veterans Administration The use of TZD rosiglitazone at least a year> 40 years and older with diabetes (154). The clinical trials began last chemoprevention of some TZDs (155) it. However, several clinical studies have shown in patients with diabetes And increased risk of cardiovascular events associated with chronic rosiglitazone Pioglitazone treatment (156-158). Designed specifically for clinical trials of potential To address the effects of TZDs on cancer and heart as a result, there is a need now.
Anti-inflammatory and anti-tumor effects of TZDs, if reached across the road More selective and lead to poisoning of the heart and blood vessels and the various candidates Drug molecules may, without leading to ill-treatment to be effective Cardiac events. And COX - 2 inhibitors, as is the case for the use of TZDs There is a need to chemoprevention of lung cancer risk assessment for the patient carefully To reduce the risk to benefit ratio is chosen is ideal for enhancing the effectiveness of Clinical trials in the future. Cox rise - are associated with decreased PPARg expression in both the poor and 2Announced lung cancer (125 159), and several recent studies and diagnosis Cox suggests PPARg -interactions between the two paths. Downstream target Cox - may be useful in the light of recent evidence that two of the intervention COX - 2 مايو enzyme activity, and events, the heart and blood vessels (160) increase the risk. Commercial PPARg agonists discovered the specific PGE2 levels in particular can reduce the Or the expression of EP receptors, which can help you develop a strategy to reduce Without affecting the production of the serious negative effects of heart disease,prostaglandin Eicosanoids. There is a need for more research to identify these opportunities and others. Especially PGE2 production, metabolism, and interfere with Effects downstream.